Hemorheological disorders in patients with peripheral occlusive arterial disease and ways to correct them
A. Zamyshliaev
, I. Tikhomirova
, A. Muravyov
, N. Antonova
, I. Velcheva
Резюме: In vascular pathology, the reserve of vascular dilatation decreases, and the rheological properties of blood can either compensate for this negative modification or worsen tissue perfusion in a given vascular region. In view of the above, the purpose of this study was to investigate the hemorheological profile in patients with peripheral occlusive arterial disease (POAD). In 26 patients with POAD blood viscosity (BV1 and BV2) at high and low shear stresses, plasma viscosity (PV) and red blood cell (RBC) suspension viscosity (SV), hematocrit (Hct), red blood cell deformability (RBCD) and their aggregation (RBCA) were recorded and compared with the blood rheology of healthy individuals. In in vitro experiments, RBC microrheological responses to biologically active compounds –signaling molecules that have a positive effect on RBC microrheology, were analyzed. It was found that most of the hemorheological characteristics were abnormally changed in patients compared with healthy individuals. To a somewhat greater extent, this concerned the RBC microrheological parameters. The RBC incubation with pentoxifylline and vinpocetine revealed a positive microrheological effect. To analyze possible molecular cellular targets for the above compounds, experiments were performed with the incubation of erythrocytes with stimulators of adenylate cyclase (Forskolin), guanylate cyclase (nitric oxide), dB-cAMP (dibutyryl – cAMP), and sodium nitroprusside (SNP). Statistically significant positive RBC microrheological responses to these compounds were obtained. Taken together, it can be concluded that in POAD, along with vascular pathology, there is a negative change in the hemorheological profile. However, the data obtained in in vitro experiments indicate the possibility of correcting the existing changes in the RBC microrheology of patients.
Series on Biomechanics, Vol.37, No.3 (2023), 3-10
Ключови думи: hemorheological profile; microrheology; phosphodiesterase (PDE) inhibitors; POAD; red blood cells; signaling molecules
| Литература: (click to open/close) | [1] Koenig, W., Ernst, E., 1992. The possible role of hemorheology in atherothrombogenesis, Atherosclerosis, 94, 93–107.
[1] Jung, F., Erdlenbruch, W., Koscielny, H., Kiesewetter, H., 1995. Influence of hyper-/isovolaemic haemodilution with hydroxyethyl starch on blood fluidity, blood flow and tissue oxygen tension in patients with POAD stage II, Clinical Hemorheology and Microcirculation, 15, 3, N3, P. 415., vol. 16, no. 3, pp. 329-342, 1996.
[3] Bolokadze, N., Lobjanidze, I., Momtselidze, N., Solomonia, R., Shakarishvili, R., Mchedlishvili, G., 2004. Blood rheological properties and lipid peroxidation in cerebral and systemic circulation of neurocritical patients, Clinical Hemorheology and Microcirculation, 30, 99–105.
[4] Koscielny, J., Jung, E.M., Mrowietz, C., Kiesewetter, H., Latza, R., 2004. Blood fluidity, fibrinogen, and cardiovascular risk factors of occlusive arterial disease: Results of the Aachen study, Clinical Hemorheology and Microcirculation, 31, 3, 185–195.
[5] Velcheva, I., Antonova, N., Titianova, E., Damianov, P., DimitrovN., Dimitrova, V., 2008. Hemorheological disturbances in cerebrovascular diseases, Clinical Hemorheology and Microcirculation, 39, 1-4, 391–396.
[6] Jung, F., 2010. From hemorheology to microcirculation and regenerative medicine: Fahraeus Lecture 2009, Clinical Hemorheology and Microcirculation, 45, 2-4, 79–99.
[7] van der Loo, B., Spring, S., Koppensteiner, R., 2011. High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clinical Hemorheology and Microcirculation, 47, 4, 241-251. doi: 10.3233/CH-2011-1386.
[8] Musielak, M., 2009. Red blood cell deformability measurement: Review of techniques, Clinical Hemorheology and Microcirculation, 42, 47–64.
[9] Stadnick, H., Onell, R., Acker, J.P., Holovati, J.L., 2011. Eadie-Hofstee analysis of red blood cell deformability, Clinical Hemorheology and Microcirculation, 47, 3, 229–239.
[10] Kim, S., Popel, A.S., Intaglietta, M., Johnson, P.C., 2005. Aggregate formation of erythrocytes in postcapillary venules, Am J Physiol Heart Circ Physiol, 288, H584–H590.
[11] Kaliviotis, E., Ivanov, I., Antonova, N., Yianneskis, M., 2010. Erythrocyte aggregation at non-steady flow conditions: A comparison of characteristics measured with electrorheology and image analysis, Clinical Hemorheology and Microcirculation, 44, 1, 43–54.
[12] Tanczos, B., Somogyi, V., Bombicz, M., Juhasz, B., Nemeth, N., Deak, A., 2021. Changes of Hematological and Hemorheological Parameters in Rabbits with Hypercholesterolemia. Metabolites. 11, 4, 249; doi: 10.3390/metabo11040249.
[13] Baskurt, O.K., Yalcin, O., Ozdem, S., Armstrong, J.K., Meiselman, H.J., 2004. Modulation of endothelial nitric oxide synthase expression by red blood cell aggregation, Am J Physiol Heart Circ Physiol, 286, H222–H228.
[14] Lowe, G.D., 1987. Blood rheology in vitro and in vivo, Baillieres Clin Haematol 1, 597–636.
[15] Ehrly, A. 1979. The effect of pentoxifylline on deformability of erythrocytes and of muscular oxygen pressure in patients with chronic arterial disease, J Med, 10, 331–338.
[16] Endres, S., Semmler, J., Eisenbut, T., Sinba, B., 1995. The role of cyclic adenosine 3,5 -monophosphate in suppression of tumor necrosis factor-α synthesis: Effect of pentoxifylline, Leukocytes and Endothelial Interactions. Prous Science. Barselona, 59–69.
[17] Muravyov, A.V., Yakusevich, V.V., Chuchkanov, F.A., Maimistova, A.A., Bulaeva, S.V., Zaitsev, L.G., 2007. Hemorheological efficiency of drugs, targeting on intracellular phosphodiesterase activity: In vitro study, Clinical Hemorheology and Microcirculation, 36, 4, 327–334.
[18] Stoltz, J.F., Donner, M., Muller, S., Larcan, A., 1991. Hemorheology in clinical practice. Introduction to the notion of hemorheologic profile. J. Mal. Vasc. 16, 3, 261-270.
[19] Muravyov, A.V., Antonova, N., Tikhomirova, I.A., 2019. Red blood cell micromechanical responses to hydrogen sulphide and nitric oxide donors: Analysis of crosstalk of two gasotransmitters (H2S and NO). Series on Biomechanics 33, 2, 34-40.
[20] Creighton, J.R., Asada, N., Cooper, D.M., Steven, T., 2003. Coordinate regulation of membrane cAMP by Ca2+-inhibited adenylyl cyclase and phosphodiesterase activities. Am J Physiol Lung Cell Mol Physiol, 284, L100–L107.
[21] Petrov V., Lijnen P. 1996. Regulation of human erythrocyte Na+/H+ exchange by soluble and particulate guanylate cyclase. Am. J. Physiol. 271, C1556–1564.
[22] Minetti G., Ciana A., Balduini C. 2004. Differential sorting of tyrosine kinases and phosphotyrosine phosphatases acting on band 3 during vesiculation of human erythrocytes. Biochem. J. 377, 489–497.
[23]Saldanha C., Silva A.S., Gonçalves S., Martins-Silva J. 2007. Modulation of erythrocyte hemorheological properties by band 3 phosphorylation and dephosphorylation. Clinical Hemorheology and Microcirculation, 36, 3, 183–194.
[24] Hausladen, A., Qian, Z., Zhang, R., Premont, R.T., Stamler, J.S., 2022. Optimized S-nitrosohemoglobin Synthesis in Red Blood Cells to Preserve Hypoxic Vasodilation Via βCys93. J Pharmacol Exp Ther. 382(1),1-10. doi: 10.1124/jpet.122.001194.
[25] O’Donnell, J.M., Frith, S., 1999. Behavioral Effects of Family-Selective Inhibitors of Cyclic Nycleotide Phosphodiesterases. Pharmacology Biochemistry and Behavior. 63 , 1,185-192.
[26] Phillips, P.G., Long, Lu, Wilkins, M. R., Morrell, N.W., 2005. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol., 288, L103-L115.
[27] Evgenov, O.V., Cornelius, J., Busch, Evgenov, N.V. et al., 2006. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol., 290, L723-L729.
[28] Muravyov, A.V., Tikhomirova, I.A. 2012. Role Ca2+ in mechanisms of the red blood cells microrheological changes. Adv. Exp. Med. Biol., 740, 1017–1038. doi: 10.1007/978-94-007-2888-2_47
[29] O’Rear E.A., Udden M.M., Farmer J.A., et al., 1984. Increased intracellular calcium and decreased deformability of erythrocytes from prosthetic heart valve patients. Clinical Hemorheology, 4, 5, 461-471.
[30] Takakuwa, Y., Mohandas, N., Ishibashi, T., 1990. Regulation of red cell membrane deformability and stability by skeletal protein network. Biorheology, 27, 3-4, 357-65.
[31] Oonishi, T., Sakashita, K., Uyesaka, N., 1997. Regulation of red blood cell filterability by Ca2+ influx and cAMP- mediated signaling pathways. Am J Physiol., 273, 6, C1828-34. doi: 10.1152/ajpcell.1997.273.6.C1828. PMID: 9435486.
[32] Ling, E., Danilov, Y.N., Cohen, C.M., 1988. Modulation of red cell band 4.1 function by cAMP-dependent kinase and protein kinase C phosphorylation. Journal of Biological Chemistry, 263, 5, 2209-2216.
[33] Oliveira, S., Silva-Herdade, A.S., Saldanha, C., 2008. Modulation of erythrocyte deformability by PKC activity. Clinical Hemorheology and Microcirculation, 39, 1-4, 363–373.
|
|
| Дата на публикуване: 2023-08-02
Свали пълен текст (Price of one pdf file: 39.00 BGN/20.00 EUR)
